F8

(redirected from coagulation factor VIII)
Also found in: Medical.
AcronymDefinition
F8Coagulation Factor VIII
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
What is observed is that despite affecting the overall budget of the Unified Health System with millions of reais, the purchase of coagulation factor VIII is carried out by the Ministry of Health, and the drug is only dispensed by the Federal District.
A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels.
Catabolism of the coagulation factor VIII: can we prolong lifetime of factor VIII in circulation?
Desmopressin, or 1-deamino-8-D-arginine vasopressin is a synthetic arginine vasopressin analog that increases the levels of plasma coagulation factor VIII and vWF [sup][1],[2] and improves PLT function.
In cases of hemophilia A, these tests measure coagulation factor VIII. Hemophilic dogs have a marked reduction in factor VIII activity compared to normal dogs.
Her factor VIII level was 2.3% and her factor VIII inhibitor level was 25 Bethesda units (measure of the level of inhibitor to coagulation factor VIII; equal to the amount of inhibitor in patient plasma that will inactivate 50% of factor VIII in an equal volume of normal plasma after a 2-h incubation period.
Haemophilia A is an X-linked recessive genetic defect, with a frequency of approximately 1 in 8,500 live births, resulting in coagulation factor VIII deficiency and bleeding diathesis.
Acquired hemophilia A is a rare, but devastating bleeding disorder caused by spontaneous development of autoantibodies directed against coagulation factor VIII. In 40%-50% of patients it is associated with such conditions as the postpartum period, malignancy, use of medications, and autoimmune diseases; however, its cause is unknown in most cases.
Based on an updated analysis of the risk, the FDA "continues to believe" that the risk of vCJD in patients who receive U.S.-licensed plasma-derived coagulation factor VIII products "is likely to be extremely small, although we do not know the risk with certainty."
VWD is associated with a defect in primary hemostasis and is also associated with a secondary defect in coagulation factor VIII. (3) VWD was first described in a five-year-old Finnish girl by Eric von Willebrand in 1926.
Bayer Kogenate(r)FS (Antihemophilic Factor [Recombinant]) / KOGENATE(r) Bayer (Recombinant Coagulation Factor VIII [octocog alfa]) is a recombinant factor VIII treatment indicated for the treatment of hemophilia A.
Full browser ?